Ascendis Pharma A/S (NASDAQ:ASND) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note published on Monday morning, Benzinga reports. They currently have a $170.00 price objective on the biotechnology company’s stock.

Other equities analysts also recently issued research reports about the stock. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a research note on Wednesday, September 4th. TD Cowen lowered their price target on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a buy rating on the stock in a research note on Wednesday, September 4th. Stifel Nicolaus started coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They issued a buy rating and a $200.00 target price on the stock. Evercore ISI raised shares of Ascendis Pharma A/S to a strong-buy rating in a research note on Monday, August 26th. Finally, Oppenheimer raised shares of Ascendis Pharma A/S from a market perform rating to an outperform rating and set a $180.00 target price for the company in a research note on Thursday, September 5th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $187.08.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $139.57 on Monday. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The stock’s 50 day simple moving average is $132.51 and its 200-day simple moving average is $136.47. The stock has a market cap of $8.13 billion, a P/E ratio of -14.52 and a beta of 0.63.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP lifted its position in Ascendis Pharma A/S by 257.1% during the second quarter. Quarry LP now owns 2,500 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 1,800 shares during the last quarter. Algert Global LLC raised its stake in Ascendis Pharma A/S by 54.6% in the 2nd quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 770 shares during the period. Lighthouse Investment Partners LLC purchased a new position in Ascendis Pharma A/S in the 2nd quarter valued at approximately $2,762,000. Fred Alger Management LLC grew its position in shares of Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new stake in shares of Ascendis Pharma A/S in the second quarter worth $4,931,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.